Abstract
Multiple sclerosis (MS) is a complex neurological disorder characterized by inflammation and degeneration of the central nervous system, primarily involving the white matter. On the basis of a wide body of evidence in experimental models and in affected patients, several attempts to treat MS using drugs which modulate immune reactions have been performed or are currently ongoing. However, it should be stressed that inflammation does not have only a detrimental effect in MS. In fact, parts of the inflammatory events are crucial for the control and conclusion of the acute phase of damage and it is probable that they actually favor regeneration and recovery. Due to the above, several trials with immunosuppressant drugs failed or were suspended because of unexpected worsening of the course of MS. The knowledge of MS immunopathogenesis is so rapidly evolving that any attempt to review it is in some way frustrating. On the other hand, this evolution is at the basis of the several new treatment options which can be hypothesized for this disease. The current status of immunosuppression in MS and the possible future development of MS treatment will be reviewed, with particular reference to those treatments which have already been tested in clinical trials and which are based on sound evidence of a putative interference with specific events occurring in MS, with the sparing of general immunity.
Keywords: immunosuppression, pathogenesis, inflammation, treatment, Multiple sclerosis
Current Medicinal Chemistry
Title: Current Status and Future Prospective of Immunointervention in Multiple Sclerosis
Volume: 13 Issue: 19
Author(s): Guido Cavaletti
Affiliation:
Keywords: immunosuppression, pathogenesis, inflammation, treatment, Multiple sclerosis
Abstract: Multiple sclerosis (MS) is a complex neurological disorder characterized by inflammation and degeneration of the central nervous system, primarily involving the white matter. On the basis of a wide body of evidence in experimental models and in affected patients, several attempts to treat MS using drugs which modulate immune reactions have been performed or are currently ongoing. However, it should be stressed that inflammation does not have only a detrimental effect in MS. In fact, parts of the inflammatory events are crucial for the control and conclusion of the acute phase of damage and it is probable that they actually favor regeneration and recovery. Due to the above, several trials with immunosuppressant drugs failed or were suspended because of unexpected worsening of the course of MS. The knowledge of MS immunopathogenesis is so rapidly evolving that any attempt to review it is in some way frustrating. On the other hand, this evolution is at the basis of the several new treatment options which can be hypothesized for this disease. The current status of immunosuppression in MS and the possible future development of MS treatment will be reviewed, with particular reference to those treatments which have already been tested in clinical trials and which are based on sound evidence of a putative interference with specific events occurring in MS, with the sparing of general immunity.
Export Options
About this article
Cite this article as:
Cavaletti Guido, Current Status and Future Prospective of Immunointervention in Multiple Sclerosis, Current Medicinal Chemistry 2006; 13 (19) . https://dx.doi.org/10.2174/092986706777935168
DOI https://dx.doi.org/10.2174/092986706777935168 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Overcoming the Drug Resistance Problem with Second-Generation Tyrosine Kinase Inhibitors: From Enzymology to Structural Models
Current Medicinal Chemistry Galanin: A Novel Therapeutic Target for Depression, Anxiety Disorders and Drug Addiction?
CNS & Neurological Disorders - Drug Targets Brain Norepinephrine System as a Target for Antidepressant and Mood Stabilizing Medications
Current Drug Targets Conference Report (8th Annual Meeting of the Society for the Study of Neuroprotection and Neuroplasticity)
CNS & Neurological Disorders - Drug Targets Meta-Analysis of the Effectiveness and Safety of Prophylactic Use of Nimodipine in Patients with an Aneurysmal Subarachnoid Haemorrhage
CNS & Neurological Disorders - Drug Targets Adenocarcinoma of the Appendix in Elderly: Diagnostic Dilemma
New Emirates Medical Journal Ocular Inflammation and Depression: Ophthalmologists’ Perspective
Current Topics in Medicinal Chemistry Current Status of Drug Delivery Approaches and Assay of Anti-Migraine Drugs
Current Drug Delivery Sigma Receptor Activation Reduces Infarct Size at 24 Hours After Permanent Middle Cerebral Artery Occlusion in Rats
Current Neurovascular Research The Applicability of mTOR Inhibition in Solid Tumors
Current Cancer Drug Targets Loneliness and Social Isolation: Determinants of Cardiovascular Outcomes
Current Cardiology Reviews Subject Index To Volume-3
Letters in Organic Chemistry Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease
Current Medicinal Chemistry An Overview of the Heterogeneity of Major Depressive Disorder: Current Knowledge and Future Prospective
Current Neuropharmacology Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research The Molecular and Cellular Basis of Atherosclerosis and Plaque Rupture
Current Cardiology Reviews Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Development of Pramipexole Hydrochloride Nanocrystals and their Characterization based on <I>In vitro</I> Dissolution Studies
Current Nanomedicine Is Cdc25 a Druggable Target?
Anti-Cancer Agents in Medicinal Chemistry Vehicles for Lipophilic Drugs: Implications for Experimental Design, Neuroprotection, and Drug Discovery
Current Neurovascular Research